Form 4 for INBS INTELLIGENT BIO SOLUTIONS INC.
Accepted 2024-03-21 00:00:00 ET · period of report 2024-03-20 · accession 0001493152-24-010846 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2024-03-21 | 2024-03-20 | INBS | Sakiris Spiro Kevin | CFO | X - OptEx | — | +9,394 | 19.2K | +96% | — |
| DI | 2024-03-21 | 2024-03-20 | INBS | Sakiris Spiro Kevin | CFO | X - OptEx | $0.00 | -9,394 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-20 | X | A | 9,394 | — | 19,180 | I Held by Anest Holdings Pty Ltd | — | — | (F2) The Series F Warrants have an exercise price is $6.60 per share (after Reverse Stock Split related adjustments) and are also exercisable pursuant to an alternate cashless exercise formula set forth in the warrant. The Series F Warrants in the reported transaction were exercised pursuant to the alternate cashless exercise formula for an equal number of shares of common stock on a one-for-one basis, without payment of additional consideration therefore. (F1) The number of reported securities has been adjusted in order to reflect a 1-for-12 reverse stock split effected on January 26, 2024 (the "Reverse Stock Split"). (F4) These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director. |
| 2 | Derivative | Common Stock Warrants (Series F) | 2024-03-20 | X | D | 9,394 | $0.00 | 0 | I Held by Anest Holdings Pty Ltd | — · — to 2025-04-04 | 9,394 Common Stock | (F1) The number of reported securities has been adjusted in order to reflect a 1-for-12 reverse stock split effected on January 26, 2024 (the "Reverse Stock Split"). (F4) These securities are held by Anest Holdings Pty Ltd, as trustee of ATF S&T Sakiris Superannuation Fund, of which Mr. Sakiris is a director. (F2) The Series F Warrants have an exercise price is $6.60 per share (after Reverse Stock Split related adjustments) and are also exercisable pursuant to an alternate cashless exercise formula set forth in the warrant. The Series F Warrants in the reported transaction were exercised pursuant to the alternate cashless exercise formula for an equal number of shares of common stock on a one-for-one basis, without payment of additional consideration therefore. (F3) The Series F Warrants became exercisable on November 17, 2023, the date the Issuer's stockholders approved, for purposes of complying with Nasdaq Listing Rules 5635(c) and (d), the issuance of the shares underlying the Series F Warrants. |